Foresite’s James Tananbaum acquires 140,000 Latigo Biotherapeutics shares for $2.52 million
LTGO•Latigo Biotherapeutics director reports share acquisitions
Latigo Biotherapeutics director James B. Tananbaum reported acquiring 3,562,984 shares of common stock through Foresite Capital Fund V.
Foresite Capital Fund VI reported holdings rising to 2,203,800 shares, including a 140,000-share purchase at $18.
Foresite Capital Opportunity Fund V reported holdings increasing to 3,414,544 shares of common stock.
